Goldman Sachs Group Inc. Reiterates “GBX 4,000” Price Target for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN) has been assigned a GBX 4,000 ($52.21) price target by analysts at Goldman Sachs Group Inc. in a note issued to investors on Tuesday. The firm presently has a a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price target would suggest a potential downside of 21.35% from the stock’s previous close.
Several other equities research analysts have also issued reports on the company. JPMorgan Chase & Co. reissued a “neutral” rating and set a GBX 4,900 ($63.96) price objective on shares of AstraZeneca plc in a research note on Monday, October 3rd. BNP Paribas reissued a “neutral” rating and set a GBX 5,200 ($67.88) price objective on shares of AstraZeneca plc in a research note on Friday, September 30th. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, September 28th. Deutsche Bank AG reissued a “buy” rating and set a GBX 5,800 ($75.71) price objective on shares of AstraZeneca plc in a research note on Wednesday, September 28th. Finally, Citigroup Inc. reaffirmed a “buy” rating on shares of AstraZeneca plc in a research note on Friday, September 23rd. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) traded up 1.19% during midday trading on Tuesday, reaching GBX 5086.00. The company had a trading volume of 3,384,720 shares. The company has a 50-day moving average price of GBX 5,005.11 and a 200-day moving average price of GBX 4,435.88. The stock’s market capitalization is GBX 64.34 billion. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/09/goldman-sachs-group-inc-reiterates-gbx-4000-price-target-for-astrazeneca-plc-azn.html
The company also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were issued a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.